CHICAGO—Findings from an expanded phase I study in 107 patients with metastatic melanoma suggest that PD-1 inhibition with the novel agent nivolumab could bring extended remissions. Sarah Maxwell heard the latest at the American Society of Clinical Oncology’s 2013 meeting in Chicago from Dr. Mario Sznol MD, Clinical Research Program Leader at Yale Cancer Center, New Haven, CT and Dr. Lynn Schuchter Chief of Hematolgy/Oncology at the Abramson Cancer Center, University of Pennsylvania, Philadelphia.
You may also like...
Whole Brain Radiotherapy Does Not Benefit Patients with Brain Metastases from Lung Cancer—European Respiratory Society 2016 Congress 5 Sep, 2016 ASCO Annual Meeting Daily News Podcasts – June 3rd, 2007 4 Jun, 2007 Chronic Myeloid Leukemia ‘To Become A Very Indolent Disease’: Pregnancy Possible, Transplants Avoided—Mission Accomplished? 21 Apr, 2009 ASCO Audio Journal of Oncology – May 1st, 2006 – In the company of Gordon McVie 1 May, 2006
- Previous story Combination immunotherapy improved overall survival in patients with metastatic melanoma
- Next story Novel oral anticoagulants: latest opinion from the ESC congress
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014